Evicenter
MarkdownMedical informationP&T meetings
Cretostimogene grenadenorepvec (CG0070)

BCG-unresponsive high-risk non-muscle-invasive bladder cancer

Manufacturer
CG Oncology
Launch
Not announced
Last updated
161 sources

Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care

Interleukin-15 receptor agonists

11 evidence topics · 6 sources

QUILT-3.032 Cohort A: efficacy in the prescribing information
EndpointNogapendekin alfa inbakicept-pmln with TICE BCG
Participants“n=77”
Complete response rate (95% CI)“62% (51, 73)”
Duration of response, range in months“0.0, 47.0+”
Duration of response ≥12 months, % (n)“58% (28)”
Duration of response ≥24 months, % (n)“40% (19)”
Basis of duration of response“Based on 48 patients that achieved a complete response at any time”